CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
This is a prospective study using customized adherence enhancement (CAE) and long-acting
injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for
treatment non-adherence. The CAE approach is expected to improve treatment adherence, as well
as improve BD symptoms, functioning and treatment attitudes among subjects with bipolar
disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Martha Sajatovic
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.